Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2026 | Optimizing outcomes for patients with migraine who have a partial response to eptinezumab

Alessandro Visentini • 27 Jun 2026
EAN 2026
Headache Antibodies Eptinezumab

Alessandro Visentini, MD, IRCCS San Raffaele Scientific Institute, Milan, Italy, shares guidance for optimizing outcomes for patients with migraine who have a partial response to eptinezumab. Dr Visentini highlights the importance of defining “partial response” and approaches to improve responses or switch therapies. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

PACAP-38 is increased in the tear fluid of patients with migraine
1:50
PACAP-38 is increased in the tear fluid of patients with migraine
Marina Romozzi • 27 Jun 2026
The gut-brain axis in the pathophysiology of pediatric migraine
4:18
The gut-brain axis in the pathophysiology of pediatric migraine
Sara Pavitt • 30 Apr 2026
Rimegepant in pediatric migraine: a retrospective chart review study
1:36
Rimegepant in pediatric migraine: a retrospective chart review study
Sara Pavitt • 30 Apr 2026
Unmet needs in the management of pediatric migraine
1:34
Unmet needs in the management of pediatric migraine
Sara Pavitt • 30 Apr 2026
The content of VJNeurology is intended for healthcare professionals